[1]
|
Goettsch, W.G., Bos, S.D., Breekveldt-Postma, N., Casparie, M., Herings, R.M. and Hogendoorn, P.C. (2005) Incidence of Gastrointestinal Stromal Tumours Is Underestimated: Results of a Nation-Wide Study. European Journal of Cancer, 41, 2868-2872. https://doi.org/10.1016/j.ejca.2005.09.009
|
[2]
|
Kindblom, L.G., Remotti, H.E., Aldenborg, F. and Meis-Kindblom, J.M. (1998) Gastrointestinal Pacemaker Cell Tumor (GIPACT): Gastrointestinal Stromal Tumors Show Phenotypic Characteristics of the Interstitial Cells of Cajal. The American Journal of Pathology, 152, 1259-1269.
|
[3]
|
Ma, G.L., Murphy, J.D., Martinez, M.E. and Sicklick, J.K. (2015) Epidemiology of Gastrointestinal Stromal Tumors in the Era of Histology Codes: Results of a Population-Based Study. Cancer Epidemiology, Biomarkers & Prevention, 24, 298-302. https://doi.org/10.1158/1055-9965.EPI-14-1002
|
[4]
|
Joensuu, H., Vehtari, A., Riihimaki, J., Nishida, T., Steigen, S.E., Brabec, P., et al. (2012) Risk of Recurrence of Gastrointestinal Stromal Tumour after Surgery: An Analysis of Pooled Population-Based Cohorts. The Lancet Oncology, 13, 265-274. https://doi.org/10.1016/S1470-2045(11)70299-6
|
[5]
|
Aghdassi, A., Christoph, A., Dombrowski, F., Doring, P, Barth, C., Christoph, J., et al. (2018) Gastrointestinal Stromal Tumors: Clinical Symptoms, Location, Metastasis Formation, and Associated Malignancies in a Single Center Retrospective Study. Digestive Diseases, 36, 337-345. https://doi.org/10.1159/000489556
|
[6]
|
DeMatteo, R.P., Lewis, J.J., Leung, D., Mudan, S.S., Woodruff, J.M. and Brennan, M.F. (2000) Two Hundred Gastrointestinal Stromal Tumors: Recurrence Patterns and Prognostic Factors for Survival. Annals of Surgery, 231, 51-58.
https://doi.org/10.1097/00000658-200001000-00008
|
[7]
|
Martin, J., Poveda A., Llombart-Bosch, A., Ramos, R., Lopez-Guerrero, J.A., Garcia Del Muro, J., et al. (2005) Deletions Affecting Codons 557-558 of the C-KIT Gene Indicate a Poor Prognosis in Patients with Completely Resected Gastrointestinal Stromal Tumors: A Study by the Spanish Group for Sarcoma Research (GEIS). Journal of Clinical Oncology, 23, 6190-6198. https://doi.org/10.1200/JCO.2005.19.554
|
[8]
|
Bannon, A.E., Klug, L.R., Corless, C.L. and Heinrich, M.C. (2017) Using Molecular Diagnostic Testing to Personalize the Treatment of Patients with Gastrointestinal Stromal Tumors. Expert Review of Molecular Diagnostics, 17, 445-457.
https://doi.org/10.1080/14737159.2017.1308826
|
[9]
|
Heinrich, M.C., Corless, C.L., Demetri, G.D., Blanke, C.D., Von Mehren, M., Joensuu, H., et al. (2003) Kinase Mutations and Imatinib Response in Patients with Metastatic Gastrointestinal Stromal Tumor. Journal of Clinical Oncology, 21, 4342-4349. https://doi.org/10.1200/JCO.2003.04.190
|
[10]
|
Heinrich, M.C., Owzar, K., Corless, C.L., Hollis, D., Borden, E.C., Fletcher, CD., et al. (2008) Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III. Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. Journal of Clinical Oncology, 26, 5360-5367. https://doi.org/10.1200/JCO.2008.17.4284
|
[11]
|
von Mehren, M, Randall, R.L., Benjamin, R.S., Boles, S., Bui, M.M., Ganjoo, K.N., et al. (2018) Soft Tissue Sarcoma, Version 2.2018, NCCN. Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 16, 536-563. https://doi.org/10.6004/jnccn.2018.0025
|
[12]
|
Casali, P.G., Abecassis, N., Aro, H.T., Bauer, S., Biagini, R., Bielack, S., et al. (2018) Gastrointestinal Stromal Tumours: ESMO-EURACAN. Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 29, iv68-iv78.
|
[13]
|
De Matteo, R.P., Ballman, K.V., Antonescu, C.R., Corless, C., Kolesnikova, V., Von Mehren, M., et al. (2013) GSTftAfCTiO. American College of Surgeons Oncology Group Intergroup Adjuvant. Long-Term Results of Adjuvant Imatinib Mesylate in Localized, High-Risk, Primary Gastrointestinal Stromal Tumor: ACOSOG Z9000 (Alliance) Intergroup Phase 2 Trial. Annals of Surgery, 258, 422-429. https://doi.org/10.1097/SLA.0b013e3182a15eb7
|
[14]
|
Corless, C.L., Ballman, K.V., Antonescu, CR., Kolesnikova, V., Maki, R.G., Pisters, P.W., et al. (2014) Pathologic and Molecular Features Correlate with Long-Term Outcome after Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial. Journal of Clinical Oncology, 32, 1563-1570.
https://doi.org/10.1200/JCO.2013.51.2046
|
[15]
|
Casali, P.G., Le Cesne, A., Poveda Velasco, A., Kotasek, D., Rutkowski, P., Hohenberger, P., et al. (2015) Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI. Stromal Tumors Treated with Imatinib as an Adjuvant: A. European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration with the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. Journal of Clinical Oncology, 33, 4276-4283. https://doi.org/10.1200/JCO.2015.62.4304
|
[16]
|
Joensuu, H., Eriksson, M., Sundby Hall, K., Hartmann, J.T., Pink, D., Schutte, J., et al. (2012) One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor: A Randomized Trial. JAMA, 307, 1265-1272.
https://doi.org/10.1001/jama.2012.347
|
[17]
|
Cameron, S. (2018) Long-Term Adjuvant Treatment of Gastrointestinal Stromal Tumors (GIST) with Imatinib-A Comment and Reflection on the PERSIST-5 Study. Translational Gastroenterology and Hepatology, 3, Article No. 16.
https://doi.org/10.21037/tgh.2018.03.01
|
[18]
|
Kanda, T., Nishida, T., Wada, N., Kobayashi, O., Yamamoto, M., Sawaki, A., et al. (2013) Adjuvant Therapy with Imatinib Mesylate after Resection of Primary High-Risk Gastrointestinal Stromal Tumors in Japanese Patients. International Journal of Clinical Oncology, 18, 38-45. https://doi.org/10.1007/s10147-011-0339-7
|
[19]
|
Patrikidou, A., Domont, J., Chabaud, S., Ray-Coquard, I., Coindre, J.M., Bui-Nguyen, B., et al. (2016) Long-Term Outcome of Molecular Subgroups of GIST Patients Treated with Standard-Dose Imatinib in the BFR14 Trial of the French Sarcoma Group. European Journal of Cancer, 52, 173-180. https://doi.org/10.1016/j.ejca.2015.10.069
|
[20]
|
Debiec-Rychter, M., Dumez, H., Judson, I., Wasag, B., Verweij, J., Brown, M., et al. (2004) Use of C-KIT/PDGFRA Mutational Analysis to Predict the Clinical Response to Imatinib in Patients with Advanced Gastrointestinal Stromal Tumours Entered on Phase I and II Studies of the EORTC. Soft Tissue and Bone Sarcoma Group. European Journal of Cancer, 40, 689-695. https://doi.org/10.1016/j.ejca.2003.11.025
|
[21]
|
Corless, C.L., Schroeder, A., Griffith, D., Town, A., McGreevey, L., Harrell, P., et al. (2005) PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and in Vitro Sensitivity to Imatinib. Journal of Clinical Oncology, 23, 5357-5364. https://doi.org/10.1200/JCO.2005.14.068
|
[22]
|
von Mehren, M., Kane, J.M., Bui, M.M., Choy, E., Connelly, M., Dry, S., et al. (2020) NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021. Journal of the National Comprehensive Cancer Network, 18, 1604-1612.
https://doi.org/10.6004/jnccn.2020.0058
|
[23]
|
Casali, P.G., Blay, J.Y., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., et al. (2022) Gastrointestinal Stromal Tumours: ESMO-EURACAN-GENTURIS. Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 33, 20-33. https://doi.org/10.1016/j.annonc.2021.09.005
|
[24]
|
Joensuu, H., Eriksson, M., Hall, K.S., Hartmann, J.T., Pink, D., Schutte, J., et al. (2014) Risk Factors for Gastrointestinal Stromal Tumor Recurrence in Patients Treated with Adjuvant Imatinib. Cancer, 120, 2325-2333.
https://doi.org/10.1002/cncr.28669
|
[25]
|
Blanke, C.D., Rankin, C., Demetri, G.D., Ryan, C.W., Von Mehren, M., Benjamin, R.S., et al. (2008) Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate at Two Dose Levels in Patients with Unresectable Or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033. Journal of Clinical Oncology, 26, 626-632. https://doi.org/10.1200/JCO.2007.13.4452
|
[26]
|
Zhao, Q., Zhang, C., Qi, C., Yang, J., Chen, Y., Ge, S., et al. (2021) Preclinical Model-Based Evaluation of Imatinib Resistance Induced by KIT Mutations and Its Overcoming Strategies in Gastrointestinal Stromal Tumor (GIST). American Journal of Translational Research, 13, 13608-13624.
|
[27]
|
Eisenberg, B.L., Harris, J., Blanke, C.D., Demetri, G.D., Heinrich, M.C., Watson, J.C., et al. (2009) Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate (IM) for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumor (GIST): Early Results of RTOG 0132/ACRIN 6665. Journal of Surgical Oncology, 99, 42-47.
https://doi.org/10.1002/jso.21160
|
[28]
|
Van Den Abbeele, A.D., Gatsonis, C., De Vries, D.J., Melenevsky, Y., Szot-Barnes, A., Yap, J.T., et al. (2012) ACRIN 6665/RTOG 0132 Phase II Trial of Neoadjuvant Imatinib Mesylate for Operable Malignant Gastrointestinal Stromal Tumor: Monitoring with 18F-FDG PET and Correlation with Genotype and GLUT4 Expression. Journal of Nuclear Medicine, 53, 567-574. https://doi.org/10.2967/jnumed.111.094425
|
[29]
|
McAuliffe, J.C., Hunt, K.K., Lazar, A.J., Choi, H., Qiao, W., Thall, P., et al. (2009) A Randomized, Phase II Study of Preoperative Plus Postoperative Imatinib in GIST: Evidence of Rapid Radiographic Response and Temporal Induction of Tumor Cell Apoptosis. Annals of Surgical Oncology, 16, 910-919. https://doi.org/10.1245/s10434-008-0177-7
|
[30]
|
Kurokawa, Y., Yang, H.K., Cho, H., Ryu, M.H., Masuzawa, T., Park, S.R., et al. (2017) Phase II Study of Neoadjuvant Imatinib in Large Gastrointestinal Stromal Tumours of the Stomach. British Journal of Cancer, 117, 25-32.
https://doi.org/10.1038/bjc.2017.144
|
[31]
|
Wang, D., Zhang, Q., Blanke, C.D., Demetri, G.D., Heinrich, M.C., Watson, J.C., et al. (2012) Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-Term Follow-Up Results of Radiation Therapy Oncology Group 0132. Annals of Surgical Oncology, 19, 1074-1080. https://doi.org/10.1245/s10434-011-2190-5
|
[32]
|
Nishida, T., Shirao, K., Sawaki, A., Koseki, M., Okamura, T., Ohtsu, A., et al. (2008) Efficacy and Safety Profile of Imatinib Mesylate (ST1571) in Japanese Patients with Advanced Gastrointestinal Stromal Tumors: a Phase II Study (STI571B1202). International Journal of Clinical Oncology, 13, Article No. 244.
https://doi.org/10.1007/s10147-007-0746-y
|
[33]
|
Choi, H., Charnsangavej, C., Faria, S.C., Macapinlac, H.A., Burgess, M.A., Patel, S.R., et al. (2007) Correlation of Computed Tomography and Positron Emission Tomography in Patients with Metastatic Gastrointestinal Stromal Tumor Treated at a Single Institution with Imatinib Mesylate: Proposal of New Computed Tomography Response Criteria. Journal of Clinical Oncology, 25, 1753-1759. https://doi.org/10.1200/JCO.2006.07.3049
|
[34]
|
Farag, S., Geus-Oei, L.F., Van Der Graaf, W.T., Van Coevorden, F., Grunhagen, D., Reyners, A.K.L., et al. (2018) Early Evaluation of Response Using 18F-FDG PET. Influences Management in Gastrointestinal Stromal Tumor Patients Treated with Neoadjuvant Imatinib. Journal of Nuclear Medicine, 59, 194-196.
https://doi.org/10.2967/jnumed.117.196642
|